Cancer site | Total N=457 (%) | DVT/PE (N=205/252) |
---|---|---|
Lung | ||
NSCLC | 39 | 8/31 |
SCLC | 6 | 2/4 |
Mesothelioma | 5 | 1/4 |
Total | 50 (11%) | 11/39 |
Upper GI | ||
Gastro-oesophageal | 28 | 20/18 |
Hepatobiliary | 12 | 10/2 |
Pancreatic | 13 | 7/6 |
Total | 53 (11.6%) | 27/26 |
Breast | 86 (18.8%) | 51/35 |
Gynaecological | ||
Ovary | 27 | 9/18 |
Endometrium | 13 | 3/10 |
Cervix | 4 | 2/2 |
Vulva | 5 | 2/3 |
Total | 49 (10.7%) | 16/33 |
Male urological | ||
Renal | 20 | 11(5 IVC)/10 |
Bladder | 10 | 6/4 |
Prostate | 36 | 20/16 |
Genital | 5 | 3/2 |
Total | 71 (15.5%) | 39/32 |
Brain | 8 (1.8%) | 6/2 |
Colorectal | ||
Caecum | 14 | 6/8 |
Ascending/transverse/descending colon | 40 | 13/27 |
Sigmoid/rectum/anus | 59 | 21/38 |
Total | 113 (24.7%) | 40/73 |
Unknown primary | 9 (2%) | 4/5 |
Miscellaneous | 18 (3.9%) | 10/8 |
DVT, deep vein thrombosis; PE, pulmonary embolus; NSCLC, non small cell lung cancer, SCLC, small cell lung cancer; GI, gastrointestinal; IVC, inferior vena cava; VTE, venous thromboembolism.